In CKD, the prevalence of vascular calcification is also high and modulation of CaSR expression on VSMCs by calcimimetic agents (R-568) has been recently demonstrated to effectively delay progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice and secondary endpoints of the ADVANCE study [22,38]. Here, APOE is linked to chronic kidney disease.